Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853357 | 0.81 | TYR (0.40) | ALOX5PTGS2HTR2ATYR | |
| SCHEMBL2851133 | 0.80 | TYR (0.42) | ALOX5PTGS2PPARAHTR2ATYR | |
| SCHEMBL2852414 | 0.76 | TYR (0.37) | ALOX5TYR | |
| SCHEMBL11808022 | 0.71 | ALOX5 (0.53) | ALOX5PTGS2PPARAHTR2A | |
| SCHEMBL22413029 | 0.71 | ALOX5 (0.49) | ALOX5PTGS2PPARAHTR2ATYR | |
| SCHEMBL8079270 | 0.70 | LIPG (0.41) | ALOX5PTGS2PPARATYR | |
| SCHEMBL10771477 | 0.69 | AOC3 (0.54) | ALOX5PTGS2PPARAHTR2A | |
| SCHEMBL10776215 | 0.69 | AOC3 (0.54) | ALOX5PTGS2PPARAHTR2A | |
| SCHEMBL10618666 | 0.69 | ALOX5 (0.50) | ALOX5PTGS2PPARAHTR2AELANE | |
| SCHEMBL28100250 | 0.69 | AOC3 (0.54) | ALOX5PTGS2PPARAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| EP-2729479-A1 | CATALYSTS | Borealis AG (AT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007650-A1 | CATALYSTS | BOREALIS AG (AT) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024123-A1 | Asymmetrical Ligands | CCRL2, AR, CCR2 | ALOX5 4188/4885PTGS2 1902/4885PPARA 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.